Xinhua Pharmaceutical announced that the company received the “Drug Supplement Application Approval Notice” for the paramivir injection approved and issued by the State Drug Administration, and the transfer application of the product's marketing license holder was approved.
新华制药：取得帕拉米韦注射液药品补充申请批准通知书
Xinhua Pharmaceuticals: Obtaining Approval Notice for Supplemental Application for Paramivir Injectable Drugs
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.